ID, HIV experts urge more resources for TB

With drug-resistant strains of TB on the rise and progress in detecting new cases on the decline, resources are needed to support TB care, surveillance, infection control, and research into new drugs, diagnostics, and vaccines.

“The standard test for diagnosing TB is more than 100 years old and it fails to adequately detect the disease in children and people with HIV. The newest class of TB drugs is more than 40 years old and does a poor job on drug-resistant TB. Today’s TB vaccine is more than 85 years old and is not highly effective, and for that reason it is not recommended for routine use in the United States,” said Carol Dukes Hamilton, MD, an IDSA and HIVMA spokesperson who works on TB and HIV in the United States and the developing world.

TB remains one of the leading infectious disease killers worldwide, with about 9 million new cases and almost 2 million deaths each year. In the U.S. alone, about 10 million to 14 million people are estimated to be infected with latent tuberculosis. Active TB can be easily passed to others—even healthy adults and children—simply by breathing the same air. The World Health Organization estimates that nearly half a million cases of TB are resistant to first-line drugs.

In the developing world, TB is the leading killer of people with HIV. The two epidemics fuel each other in a vicious cycle. People with HIV are more susceptible to getting sick and dying from TB if they are exposed, and TB bacteria accelerate the progression of HIV to AIDS. Absent a comprehensive plan to control tuberculosis, this deadly infection threatens to undermine the gains that have been made in saving the lives of persons living with HIV in the developing world.

Legislation in both the House and Senate would devote substantial resources—$4 billion over five years—to stopping TB in the developing world through the President’s Plan for AIDS Relief (PEPFAR). PEPFAR supports HIV/AIDS programs in 15 countries that comprise 21 percent of the global TB burden and 24 percent of the world’s annual TB deaths. The program offers millions more in support of HIV prevention and treatment activities in scores of other developing countries.

“The U.S. government has been a leader in stopping HIV/AIDS in the developing world,” said Dr. Hamilton. “We must show the same bold leadership on tuberculosis; otherwise, we run the risk of losing ground on control of tuberculosis—including highly drug-resistant TB—and HIV/AIDS.”

Unfortunately, the Bush administration’s proposed budget for fiscal year 2009 includes significant cuts for TB and other infectious disease programs. Especially hard-hit is the U.S. Centers for Disease Control and Prevention (CDC), which would see a cut of nearly half a billion dollars in its total budget. IDSA supports increasing CDC’s overall budget by 15 percent and devoting $300 million for efforts to prevent, control, and eliminate tuberculosis in the United States. Likewise, IDSA supports increased resources for the National Institutes of Health (NIH)’s TB programs. NIH expects to spends about $187 million on TB in fiscal year 2009, including $17 million on efforts to find a new vaccine.

Source: Infectious Diseases Society of America

New way to make malaria medicine also first step in finding new antibiotics
University of Illinois microbiology professor William Metcalf and his collaborators have developed a way to mass-produce an antimalarial compound, potentially making the treatment of malaria less expensive.
NTDs burden in Latin America and the Caribbean may exceed that of HIV/AIDS, TB and malaria
According to a new analysis published September 24th in the open-access journal PLoS Neglected Tropical Diseases, "The Neglected Tropical Diseases of Latin America and the Caribbean: A Review of Disease Burden and Distribution and a Roadmap for Control And Elimination,", neglected tropical diseases (NTDs) as a group may have surpassed HIV/AIDS, tuberculosis and malaria as the most prevalent infectious diseases in Latin America and the Caribbean. The analysis found that NTDs are the most common infections of approximately 200 million of the poorest people in the region. They include tens of millions of cases of intestinal worm infections, and almost 10 million cases of Chagas disease, as well as schistosomiasis, trachoma, dengue fever, leishmaniasis, lymphatic filariasis (LF), and onchocerciasis.
As personalized, genomic medicine takes off, four developing countries show the way for others
Developing countries that want the benefits of cutting-edge health care possibilities based on the genetic variation of individual citizens and sub-populations need to foster the new science at home, says a major new Canadian study published today by Nature Publishing Group.
Landmark study reports breakdown in biotech patent system
The world's intellectual property system is broken. It's stopping lifesaving technologies from reaching the people who need them most in developed and developing countries, according to the authors of a report released in Ottawa today by an international coalition of experts.
Operations research promises continued gains for HIV treatment in resource-limited countries
In the past 10 years, the global campaign to expand treatment for millions of people with AIDS living in resource-limited countries, especially in sub-Saharan Africa, has gained substantial commitments in public and private financing, and has made major strides in making treatment available to those who need it. A new collaborative study by researchers at Weill Cornell Medical College and the Clinton Foundation HIV/AIDS Initiative explores how to combine engineering science with medical care to guarantee the long-term success of these treatment programs.
Nano vaccine for hepatitis B shows promise for third world
Chronic hepatitis B infects 400 million people worldwide, many of them children. Even with three effective vaccines available, hepatitis B remains a stubborn, unrelenting health problem, especially in Africa and other developing areas. The disease and its complications cause an estimated 1 million deaths globally each year.
When it comes to abstinence teens, adults aren't speaking the same language
Abstinence can mean different things to adolescents than to adults. That's one reason why abstinence-only programs do not have strong effects in preventing teenage sexual activity, according to new University of Washington research.
UT pathologists believe they have pinpointed Achilles heel of HIV
Human Immunodeficiency Virus (HIV) researchers at The University of Texas Medical School at Houston believe they have uncovered the Achilles heel in the armor of the virus that continues to kill millions.

ID, HIV experts urge more resources for TB

Related stories:

News discussion: